| 0.4523 0 (0%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.34 | 1-year : | 0.48 |
| Resists | First : | 0.29 | Second : | 0.41 |
| Pivot price | 0.18 |
|||
| Supports | First : | 0.1 | Second : | 0.08 |
| MAs | MA(5) : | 0.13 |
MA(20) : | 0.19 |
| MA(100) : | 0.28 |
MA(250) : | 1.22 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.1 |
D(3) : | 7.8 |
| RSI | RSI(14): 40.8 |
|||
| 52-week | High : | 3.57 | Low : | 0.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LHDX ] has closed above bottom band by 22.5%. Bollinger Bands are 47.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.15 - 0.15 | 0.15 - 0.15 |
| Low: | 0.12 - 0.12 | 0.12 - 0.12 |
| Close: | 0.12 - 0.13 | 0.13 - 0.13 |
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
Thu, 06 Apr 2023
Pfizer to buy Covid-flu test developer Lucira Health out of bankruptcy court - San Francisco Business Times - The Business Journals
Fri, 03 Mar 2023
Why Is Lucira Health (LHDX) Stock Down 14% Today? - InvestorPlace
Wed, 01 Mar 2023
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11 - MarketBeat
Mon, 27 Feb 2023
Lucira Health Announces FDA Authorization of First & Only At-Home Combination Covid-19 & Flu Test and Comments ... - GlobeNewswire
Thu, 23 Feb 2023
Why Is Lucira Health (LHDX) Stock Down 34% Today? - InvestorPlace
Wed, 22 Feb 2023
Covid Test Maker Lucira Goes Bankrupt as Demand for Kits Wanes - Bloomberg
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 41 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 10.1 (%) |
| Held by Institutions | 23.8 (%) |
| Shares Short | 677 (K) |
| Shares Short P.Month | 1,210 (K) |
| EPS | -3.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.5 |
| Profit Margin | -67.6 % |
| Operating Margin | -65 % |
| Return on Assets (ttm) | -41.8 % |
| Return on Equity (ttm) | -112.5 % |
| Qtrly Rev. Growth | 129.6 % |
| Gross Profit (p.s.) | 0.28 |
| Sales Per Share | 5.22 |
| EBITDA (p.s.) | -3.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -82 (M) |
| Levered Free Cash Flow | -50 (M) |
| PE Ratio | -0.05 |
| PEG Ratio | 0 |
| Price to Book value | 0.08 |
| Price to Sales | 0.02 |
| Price to Cash Flow | -0.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|